featured
Clinical Efficacy and Safety of Achieving Very Low LDL Cholesterol With the PCSK9 Inhibitor Evolocumab
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Clinical Efficacy and Safety of Achieving Very Low LDL-Cholesterol Concentrations With the PCSK9 Inhibitor Evolocumab: A Prespecified Secondary Analysis of the FOURIER Trial
Lancet 2017 Aug 25;[EPub Ahead of Print], RP Giugliano, TR Pedersen, JG Park, GM De Ferrari, ZA Gaciong, R Ceska, K Toth, I Gouni-Berthold, J Lopez-Miranda, F Schiele, F Mach, BR Ott, E Kanevsky, AL Pineda, R Somaratne, SM Wasserman, AC Keech, PS Sever, MS SabatineFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.